"McDermott Will & Schulte Advises V-Bio Ventures in €38M Series C Funding Round for Step Pharma"

"McDermott Will & Schulte advised V-Bio Ventures, the lead investor in Step Pharma's €38 million Series C funding round. This round also included existing investors such as Pontifax and BPIFrance. The funding will support Step Pharma's development of dencatistat, a highly selective oral CTPS1 inhibitor for targeted cancer treatment. The McDermott team included Anthony Paronneau, Lucie Martin, and Alice Villagrasa."

McDermott Will & Schulte advised V-Bio Ventures as the lead investor in the €38 million Series C funding round for Step Pharma, a global leader in CTPS1 inhibition for targeted cancer treatment. This funding round also included participation from existing investors Pontifax, BPIFrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures, and Inserm Transfert Initiative. The financing will enable Step Pharma to continue its pipeline strategy in a product for dencatistat, a highly selective, orally bioavailable CTPS1 inhibitor that is the first of its kind and is currently in clinical development for the treatment of cancers and blood disorders. The McDermott Will & Schulte team consisted of Anthony Paronneau, Partner; Lucie Martin, Counsel; and Alice Villagrasa, Associate.

"McDermott Will & Schulte Advises V-Bio Ventures in €38M Series C Funding Round for Step Pharma"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads